Status:
TERMINATED
Natrecor in Pulmonary Hypertension
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Pulmonary Hypertension
Cancer
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
The goal of this clinical research study is to learn if the drug nesiritide (Natrecor) is effective in lowering the pressure in your lungs. The primary objective of this study is to establish that Ne...
Detailed Description
Patients with high pressure in their lungs often have many symptoms such as, shortness of breath, low energy, and fatigue. Decreasing the pressure in the lungs may help these patients feel better. The...
Eligibility Criteria
Inclusion
- Ages 18 to 85 years old.
- Evidence of underlying lung disease by history and physical and/or chest x-ray and/or pulmonary function testing (PFT's).
- PHTN documented by Doppler Echocardiography ( Done with in last 30 days)
- Must be able to give an informed consent.
Exclusion
- Patients with clinically significant hypotension (defined as a systolic blood pressure (SBP) \<90).
- Active infection or sepsis as defined by fever and need for IV antibiotics.
- Creatinine greater than 3.0 mg/dl
- Significant valvular disease as a cause for the PHTN.
- Severe Thrombocytopenia (as defined by platelets less than 20,000 or INR \> 1.6.
- Left Ventricle Ejection Fraction (LVEF) \<40% (must be done with in the last 30 days prior to signing consent).
- Hypersensitivity to nesiritide or any of it's components.
Key Trial Info
Start Date :
December 31 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 28 2006
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00075179
Start Date
December 31 2003
End Date
March 28 2006
Last Update
November 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030